Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (Nasdaq: ARQT) has announced the grant of 35,000 restricted stock units to five newly hired employees. The grants were approved by the company's Compensation Committee and issued under the Arcutis Biotherapeutics 2022 Inducement Plan on April 1, 2025.
The restricted stock units feature a four-year vesting schedule, with 25% vesting annually on each anniversary of the vesting commencement date. Continuous employment is required for vesting. This grant was made as an employment inducement in compliance with Nasdaq Listing Rule 5635(c)(4).
Arcutis Biotherapeutics (Nasdaq: ARQT) ha annunciato l'assegnazione di 35.000 unità di azioni vincolate a cinque nuovi dipendenti. Le assegnazioni sono state approvate dal Comitato per la Compensazione dell'azienda e rilasciate nell'ambito del Piano di Induzione 2022 di Arcutis Biotherapeutics il 1° aprile 2025.
Le unità di azioni vincolate prevedono un programma di maturazione di quattro anni, con il 25% che matura annualmente ad ogni anniversario della data di inizio della maturazione. È richiesta un'occupazione continua per la maturazione. Questa assegnazione è stata effettuata come incentivo all'occupazione in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Arcutis Biotherapeutics (Nasdaq: ARQT) ha anunciado la concesión de 35,000 unidades de acciones restringidas a cinco nuevos empleados. Las concesiones fueron aprobadas por el Comité de Compensación de la empresa y emitidas bajo el Plan de Inducción 2022 de Arcutis Biotherapeutics el 1 de abril de 2025.
Las unidades de acciones restringidas cuentan con un programa de adquisición de cuatro años, con un 25% que se adquiere anualmente en cada aniversario de la fecha de inicio de la adquisición. Se requiere empleo continuo para la adquisición. Esta concesión se realizó como un incentivo laboral en cumplimiento con la Regla de Cotización Nasdaq 5635(c)(4).
Arcutis Biotherapeutics (Nasdaq: ARQT)는 다섯 명의 새로 고용된 직원에게 35,000개의 제한 주식 단위를 부여한다고 발표했습니다. 이 부여는 회사의 보상 위원회에 의해 승인되었으며, 2022년 Arcutis Biotherapeutics 유도 계획에 따라 2025년 4월 1일에 발행되었습니다.
제한 주식 단위는 4년의 분할 일정을 특징으로 하며, 매년 분할 시작일의 기념일에 25%가 분할됩니다. 분할을 위해서는 지속적인 고용이 필요합니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유인을 위해 이루어졌습니다.
Arcutis Biotherapeutics (Nasdaq: ARQT) a annoncé l'octroi de 35 000 unités d'actions restreintes à cinq nouveaux employés. Les octrois ont été approuvés par le Comité de Rémunération de l'entreprise et émis dans le cadre du Plan d'Induction 2022 d'Arcutis Biotherapeutics le 1er avril 2025.
Les unités d'actions restreintes disposent d'un calendrier d'acquisition de quatre ans, avec 25 % qui s'acquiert annuellement à chaque anniversaire de la date de début de l'acquisition. Un emploi continu est requis pour l'acquisition. Cet octroi a été réalisé comme incitation à l'emploi conformément à la règle de cotation Nasdaq 5635(c)(4).
Arcutis Biotherapeutics (Nasdaq: ARQT) hat die Gewährung von 35.000 eingeschränkten Aktieneinheiten an fünf neu eingestellte Mitarbeiter bekannt gegeben. Die Gewährungen wurden vom Vergütungsausschuss des Unternehmens genehmigt und am 1. April 2025 im Rahmen des Arcutis Biotherapeutics 2022 Induktionsplans ausgegeben.
Die eingeschränkten Aktieneinheiten verfügen über einen vierjährigen Vesting-Zeitplan, wobei 25 % jährlich am Jahrestag des Vesting-Beginns fällig werden. Kontinuierliche Beschäftigung ist für das Vesting erforderlich. Diese Gewährung wurde als Beschäftigungsanreiz in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4) vorgenommen.
- None.
- None.
WESTLAKE VILLAGE, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 35,000 restricted stock units of Arcutis’ common stock to five newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of April 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates.
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Corporate Controller
ir@arcutis.com
FAQ
How many restricted stock units did Arcutis Biotherapeutics (ARQT) grant in April 2025?
What is the vesting schedule for ARQT's April 2025 restricted stock units grant?
Under which plan were the ARQT restricted stock units granted in April 2025?
What is the purpose of ARQT's April 2025 restricted stock unit grants?
